Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Ding, Xiao-Xiao, Zhu, Qing-Ge, Zhang, Shi-Ming, Guan, Lei, Li, Ting, Zhang, Lei, Wang, Shi-Yang, Ren, Wan-Li, Chen, Xue-Mei, Zhao, Jing, Lin, Song, Liu, Zhi-Zhen, Bai, Yan-Xia, He, Bing, Zhang, Hu-Qin
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589693/
https://ncbi.nlm.nih.gov/pubmed/28903454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18382
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires